Immature Platelet Fraction as an Independent Marker of Adverse Outcomes in an Intensive Cardiovascular Care Unit

Platelet activation and thrombopoiesis are central to acute cardiovascular disease pathophysiology, yet the prognostic role of the immature platelet fraction (IPF) remains incompletely defined in heterogeneous intensive cardiovascular care unit (ICCU) populations. We conducted a single-center, observational study of 6,725 consecutive ICCU admissions with IPF measured. The primary endpoint was in-hospital all-cause mortality using multivariable logistic regression, and discrimination by receiver operating characteristic analysis. Median age was 70 years; 31.8% were women. Increasing IPF quartiles showed a stepwise rise in mortality (2.1 to 3.7%; p-trend = 0.003), acute renal failure (ARF) (2.4 to 5.1%; p < 0.001), malignant arrhythmia (0.9 to 2.2%; p = 0.002), and in-hospital cardiogenic shock (2.7 to 4.7%; p = 0.008); the regression analysis for cardiogenic shock was restricted to incident cases among non-shock admissions (n = 5,778). After multivariable adjustment, each 1 natural-log-unit increment in IPF (∼1.7× raw IPF) remained independently associated with mortality (OR 1.55, 95% CI: 1.10–2.19), ARF (OR 1.75, 1.37–2.25), malignant arrhythmia (OR 2.07, 1.44–2.98), and cardiogenic shock (OR 1.51, 1.16–1.96). Discrimination of IPF alone was modest (AUC 0.57–0.59), but incorporation into multivariable models improved performance (mortality AUC 0.78). Reclassification analysis demonstrated incremental value beyond baseline (categorical net reclassification improvement [NRI] +6.9 to +12.1%; continuous NRI 0.14–0.28). In this large, contemporary ICCU cohort, elevated IPF was independently associated with in-hospital mortality, as well as adverse outcomes. Although not a standalone discriminator, IPF is a readily available, low-cost biomarker that may enhance early mortality risk stratification when integrated with established clinical variables, supporting further evaluation in multimodal and machine learning–based prediction frameworks.

Authors

Institutions

Publication Details

Journal
Thrombosis and Haemostasis
Published
2026-09-11
DOI
https://doi.org/10.1055/a-2944-1196
Primary Topic
Inflammatory Biomarkers in Disease Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Immature Platelet Fraction as an Independent Marker of Adverse Outcomes in an Intensive Cardiovascular Care Unit

Ari Naimark, Noam Fink, Amjad Abu-Salman, Elad Asher et al.
Thrombosis and Haemostasis
Inflammatory Biomarkers in Disease Prognosis
article

Immature Platelet Fraction as an Independent Marker of Adverse Outcomes in an Intensive Cardiovascular Care Unit

Ari Naimark, Noam Fink, Amjad Abu-Salman, Elad Asher, Louay Taha, Akiva Brin, Pierre Sabouret, Mamas A. Mamas, Michael Glikson, Mohammad Karmi
article en

Abstract

Platelet activation and thrombopoiesis are central to acute cardiovascular disease pathophysiology, yet the prognostic role of the immature platelet fraction (IPF) remains incompletely defined in heterogeneous intensive cardiovascular care unit (ICCU) populations. We conducted a single-center, observational study of 6,725 consecutive ICCU admissions with IPF measured. The primary endpoint was in-hospital all-cause mortality using multivariable logistic regression, and discrimination by receiver operating characteristic analysis. Median age was 70 years; 31.8% were women. Increasing IPF quartiles showed a stepwise rise in mortality (2.1 to 3.7%; p-trend = 0.003), acute renal failure (ARF) (2.4 to 5.1%; p < 0.001), malignant arrhythmia (0.9 to 2.2%; p = 0.002), and in-hospital cardiogenic shock (2.7 to 4.7%; p = 0.008); the regression analysis for cardiogenic shock was restricted to incident cases among non-shock admissions (n = 5,778). After multivariable adjustment, each 1 natural-log-unit increment in IPF (∼1.7× raw IPF) remained independently associated with mortality (OR 1.55, 95% CI: 1.10–2.19), ARF (OR 1.75, 1.37–2.25), malignant arrhythmia (OR 2.07, 1.44–2.98), and cardiogenic shock (OR 1.51, 1.16–1.96). Discrimination of IPF alone was modest (AUC 0.57–0.59), but incorporation into multivariable models improved performance (mortality AUC 0.78). Reclassification analysis demonstrated incremental value beyond baseline (categorical net reclassification improvement [NRI] +6.9 to +12.1%; continuous NRI 0.14–0.28). In this large, contemporary ICCU cohort, elevated IPF was independently associated with in-hospital mortality, as well as adverse outcomes. Although not a standalone discriminator, IPF is a readily available, low-cost biomarker that may enhance early mortality risk stratification when integrated with established clinical variables, supporting further evaluation in multimodal and machine learning–based prediction frameworks.

Thrombosis and Haemostasis
Assuta Medical Center (IL), Shaare Zedek Medical Center (IL), Sorbonne Université (FR), Pitié-Salpêtrière Hospital (FR), Société Française de Cardiologie (FR), Keele University (GB)
Gender equality
Openalex Percentile: Top 13%
Inflammatory Biomarkers in Disease Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.